Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

As of 11th March 2015, a Phase II clinical trial of a potential Ebola treatment is underway in Sierra Leone. The trial of the therapy, TKM-Ebola-Guinea, is being led by Professor Peter Horby. TKM-Ebola-Guinea  is a synthetic small interfering RNA  therapeutic designed specifically to target the strain of the Ebola virus responsible for the present outbreak in Guinea, Liberia and Sierra Leone.

Read more